| Synaptic vesicle regulation | Alpha-synuclein modulates synaptic vesicle pooling and neurotransmitter release |
| Membrane interaction | The protein binds to lipid membranes, potentially regulating vesicle trafficking |
| Antioxidant function | Alpha-synuclein may protect neurons from oxidative stress |
| Chaperone activity | The protein has molecular chaperone properties, aiding protein folding |
| Monomeric | Unfolded, cytosolic form |
| Oligomeric | Small aggregates (toxic intermediate) |
| Fibrillar | Forms Lewy bodies in disease states |
| SNCA duplication | Causes autosomal dominant PD |
| SNCA triplication | Causes early-onset PD with rapid progression (Parkinsonism-Dementia Complex of Guam) |
| Lewy body formation | Abnormal aggregation of alpha-synuclein into insoluble fibrils |
| Synaptic dysfunction | Loss of normal protein function disrupts neurotransmitter release |
| Mitochondrial dysfunction | Alpha-synuclein toxicity affects mitochondrial quality control |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!